Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s IT Systems Painted With Bull’s-eye By Senate Funding Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

The Senate Appropriations Committee April 26 approves a $3.9 billion spending plan for the agency in fiscal 2013, providing a $12.5 million boost in Treasury spending over President Obama’s proposed budget, with the extra funds slated for the food and animal drug programs.

You may also be interested in...



FDA Seeks New Chief Information Officer As Privacy And Security Policies Get Overhaul

New CIO will help develop new policy to protect sensitive information at FDA, while also balancing individual privacy and security.

User Fee Management System Part Of CDER Plans To Enhance IT Capabilities

The need to assimilate biosimilar and generic drug user fee programs and a quest for greater efficiency are major drivers of the center’s proposed $88.9 million spending plan on information technology systems in fiscal year 2014.

House FDA Appropriations Chairman Has Budget-Cutting History

Alabama Republican Robert Aderholt takes over as House FDA appropriations subcommittee chair, while Maryland Democrat Barbara Mikulski now runs the Senate Appropriations Committee.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel